Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
2.
Georgian Med News ; (331): 78-84, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-36539135

RESUMO

SARS-CoV-2 is the cause of COVID-19 disease and responsible for a pandemic since the 2020. Multiple organ involvement has been described including cutaneous symptoms. Affection of skin appendages, however, seems to be under-reported except for COVID-toes. We performed a PUBMED research for "COVID-19" OR "SARS-CoV-2" AND "skin appendages", "hair", "nails", and "skin glands" from January 2020 to April 2022. COVID toes were excluded since this symptom had extensively been discussed. The focus of this narrative review was laid on clinical presentation, association to the course of COVID-19 disease and treatment options. Skin appendages can be affected by COVID-19 disease beyond COVID-toes, both by symptomatic and asymptomatic course. Telogen effluvium, androgenetic alopecia, and alopecia areata are the most common hair disorders in COVID-19 patients. Nails are less commonly affected by COVID-19 than hair. Splinter hemorrhages and leukonychia are the most frequent findings. While sebaceous glands seem to be uninvolved, SARS-CoV-2 spike proteins have been identified in eccrine sweat glands. Alopecia areata is often seen among asymptomatic COVID-19 patients while telogen effluvium is observed in symptomatic and asymptomatic patients. The half-moon sign on the nails could be a red flag for a more severe course of COVID-19. Treatment options are summarized. Skin appendages are not spared by COVID-19. Their knowledge will help to identify asymptomatic patients and patients at risk for a more severe course of the viral disease.


Assuntos
Alopecia em Áreas , COVID-19 , Dermatopatias , Humanos , SARS-CoV-2 , Pele , Dermatopatias/diagnóstico , Dermatopatias/terapia
3.
J Eur Acad Dermatol Venereol ; 36(11): 2076-2086, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35748102

RESUMO

BACKGROUND: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. OBJECTIVES: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. METHODS: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. RESULTS: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). DISCUSSION: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.


Assuntos
Produtos Biológicos , COVID-19 , Psoríase , Adolescente , Adulto , Fatores Biológicos/uso terapêutico , Produtos Biológicos/uso terapêutico , COVID-19/complicações , Criança , Progressão da Doença , Humanos , Metotrexato/uso terapêutico , Pandemias , Psoríase/complicações , Psoríase/tratamento farmacológico , Psoríase/epidemiologia , Sistema de Registros
6.
Hautarzt ; 72(10): 855-859, 2021 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-33884438

RESUMO

Tinea capitis is seen world-wide among children up to 12 years. The most severe type is Kerion Celsi with painful abscesses and lymphadenopathy. We report on an 11-year-old boy with Kerion Celsi, who was initially treated using antibiotics under the common misdiagnosis of a bacterial infection. Mycological investigations could identify Microsporum canis. The patient was treated orally with griseofulvin, which resulted in complete mycological remission after 8 weeks. Cicatrical alopecia, however, could not be prevented. Purulent infections of the scalp should lead to early mycological diagnostics in children.


Assuntos
Microsporum , Tinha do Couro Cabeludo , Alopecia , Antifúngicos/uso terapêutico , Criança , Humanos , Masculino , Couro Cabeludo , Tinha do Couro Cabeludo/diagnóstico , Tinha do Couro Cabeludo/tratamento farmacológico
8.
Clin Exp Dermatol ; 46(3): 462-472, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33207021

RESUMO

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.


Assuntos
COVID-19/complicações , Dermatopatias Virais/patologia , Adolescente , Anticorpos Monoclonais Humanizados/uso terapêutico , COVID-19/diagnóstico , COVID-19/patologia , Teste para COVID-19 , Criança , Fármacos Dermatológicos/uso terapêutico , Exantema/tratamento farmacológico , Exantema/patologia , Exantema/virologia , Humanos , Síndrome de Nicolau/tratamento farmacológico , Síndrome de Nicolau/patologia , Síndrome de Nicolau/virologia , Pitiríase Rósea/patologia , Pitiríase Rósea/virologia , Púrpura/tratamento farmacológico , Púrpura/patologia , Púrpura/virologia , SARS-CoV-2 , Dermatopatias Virais/tratamento farmacológico , Urticária/tratamento farmacológico , Urticária/patologia , Urticária/virologia
9.
Clin Exp Dermatol ; 46(3): 451-461, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33166429

RESUMO

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults, as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discussed one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions. In this part of the review, we describe other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.


Assuntos
COVID-19/complicações , Eritema Multiforme/virologia , Síndrome de Linfonodos Mucocutâneos/virologia , Urticária/virologia , Adolescente , COVID-19/patologia , Criança , Eritema Multiforme/patologia , Exantema/patologia , Exantema/virologia , Humanos , SARS-CoV-2 , Urticária/patologia
10.
Clin Exp Dermatol ; 46(3): 444-450, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33180982

RESUMO

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestation of COVID-19, chilblain-like lesions. In Part 2, we review other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome, while in Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children, for both COVID-19 and any other pre-existing conditions.


Assuntos
COVID-19/complicações , Pérnio/virologia , Adolescente , COVID-19/diagnóstico , COVID-19/patologia , COVID-19/terapia , Teste para COVID-19 , Pérnio/imunologia , Pérnio/patologia , Criança , Humanos , Interferon Tipo I/imunologia , Remissão Espontânea , Fatores de Risco , SARS-CoV-2 , Trombose/etiologia , Vasculite/etiologia
13.
Int J Biol Macromol ; 125: 191-202, 2019 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-30529355

RESUMO

The elasticity, soft consistency and similarity to the human body are important characteristics of the gels. Such similarities allow the hydrogels to be biocompatible and, as a consequence, they are very attractive to be applied as biomaterials. This study presents a new strategy for developing a biohybrid complex based on a natural/synthetic polymer conjugate as gel type structure enriched with quercetin, which can be a relevant biomaterial for its antimicrobial properties. There are evidenced the preparation possibilities for the natural/synthetic structure as complex gel based on hyaluronic acid conjugated with poly(itaconic anhydride­co­3,9­divinyl­2,4,8,10­tetraoxaspiro[5.5] undecane) copolymer decorated with quercetin. The effects of the composition on various properties were assessed. The chemical composition of bioconjugate gels was confirmed by FTIR spectroscopy. It was established that the new gel structures have enhanced swelling capacity and a typical gel-like behavior. The investigations evidenced the gels responsiveness to stimuli and their high elasticity. The new structures were tested as drug delivery systems. The in vitro release shows the dependence of the mechanism of release on the composition of the gels, evidencing a transport behavior which varies from the Fickian to super case II. In vivo investigations demonstrated a good biocompatibility after systemic administration in mice.


Assuntos
Materiais Biocompatíveis/química , Ácido Hialurônico/química , Polímeros/química , Animais , Géis/química , Humanos , Concentração de Íons de Hidrogênio , Masculino , Teste de Materiais , Camundongos , Estrutura Molecular , Polissacarídeos Bacterianos/química , Reologia , Análise Espectral , Temperatura
14.
Int J Biol Macromol ; 119: 974-981, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30098364

RESUMO

The study presents a novel strategy for obtaining highly ordered interpolymeric complexes based on a protein, bovine serum albumin and a synthetic polymer, poly(aspartic acid). In this approach, experimental tests were carried out in the presence of a magnetic field of different intensities, namely 0.11 T and 0.3 T produced by permanent magnets. The influence of the magnetic force on the complexation process and the resulted self-assembled structures were studied by means of FTIR spectroscopy, X-ray diffraction, DLS, SEM microscopy and in vitro assay. The changes in the FTIR spectra acquired after 24 h of exposure were connected with conformational changes in the secondary structure and increased interactions between polymers, particularly when a higher intensity field was used. Due to a large anisotropy of magnetic susceptibility characteristic to both proteins and polypeptides, the magnetic field generated ordered assemblies consisting in globular structures of nanometric dimensions. This assembly strategy using magnets, along with remote manipulation capability can provide a versatile, contact-free, and inexpensive tool to create new, complex materials with tailorable characteristics.


Assuntos
Campos Magnéticos , Peptídeos/química , Polímeros/química , Soroalbumina Bovina/química , Linhagem Celular Tumoral , Sobrevivência Celular , Difusão Dinâmica da Luz , Humanos , Polimerização , Espectroscopia de Infravermelho com Transformada de Fourier , Difração de Raios X
16.
Allergy ; 72(4): 552-561, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27569064

RESUMO

BACKGROUND: Drug provocation tests (DPT) are commonly performed as part of ß-lactam (BL) allergy workup, in case of negative skin tests (ST) and in the absence of contraindications. The recommendations of learned societies have created a frame for DPT performance, but protocols vary widely between centres, generating various hypothesis-driven protocols (i.e. empirical dosing, driven by both safety concerns and practical aspects). METHODS: The primary objective of this retrospective analysis was to detect eliciting dose thresholds (reactive doses) during BL DPT, using the survival analysis method, in order to suggest optimal step doses. Our secondary objective was to evaluate the safety of our 30-min incremental 1-day protocol. The study included all the patients explored in the Allergy Unit of the University Hospital of Montpellier (France), between September 1996 and July 2015 for a suspicion of drug hypersensitivity reaction to BLs, with negative ST and positive DPT. RESULTS: During the study period, 182 positive DPT (accounting for 171 hypersensitive patients) were analysed. We identified eliciting thresholds, and we suggest the following steps for DPT to BLs: 5-15-30-50% of daily therapeutic dose (with additional lower steps for index reactions of anaphylaxis). We confirm the safety of 1-day protocol for immediate and mild nonimmediate reactors, for both children and adults, with a surveillance period of 2 h after the last administered dose, and a prolonged surveillance after discharge of 48 h. CONCLUSION: This data-driven approach in designing DPT protocols is a step forward in improving DPT standardization, starting with the most frequently tested drugs, BL antibiotics.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Testes Cutâneos , beta-Lactamas/administração & dosagem , beta-Lactamas/efeitos adversos , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Testes Cutâneos/métodos , Avaliação de Sintomas , Fatores de Tempo , Adulto Jovem
17.
Int J Biol Macromol ; 95: 412-420, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27889338

RESUMO

Macromolecular co-assemblies built up in aqueous solutions, by using a linear polypeptide, poly(aspartic acid) (PAS), and a globular protein, bovine serum albumin (BSA), have been studied. The main interest was to identify the optimum conditions for an interpenetrated complex formation in order to design materials suitable for biomedical applications, such as drug delivery systems. BSA surface possesses several amino- and carboxylic groups available for covalent modification, and/or bioactive substances attachment. In the present study, mixtures between PAS and BSA were investigated at 37°C in dilute aqueous solution by viscometry, dynamic light scattering and zeta potential determination, as well as in solid state by AFM microscopy and dielectric spectroscopy. The experimental data have shown that the interpolymer complex formation occurs for a PAS/BSA molar ratio around 0.541.


Assuntos
Peptídeos/química , Soroalbumina Bovina/química , Água/química , Animais , Bovinos , Concentração de Íons de Hidrogênio , Modelos Moleculares , Ligação Proteica , Conformação Proteica , Soluções
18.
Clin Transl Allergy ; 6: 41, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27895895

RESUMO

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

19.
Allergy ; 71(11): 1612-1619, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27332957

RESUMO

BACKGROUND: Allergic Rhinitis Control Test (ARCT) has been validated for assessing allergic rhinitis (AR) control and identifying severe AR. The aim of the study was to assess the ARCT questionnaire as a tool for stepwise pharmacotherapy. METHODS: A standard pharmacotherapy regimen from Step 1 (oral second-generation H1 antihistamine as needed) to Step 5 (oral corticosteroid) was carried out prospectively in a Chinese AR population. The AR patients were initiated with Allergic Rhinitis and its Impact on Asthma (ARIA) appropriate step treatment and assessed with ARCT every 15 days. If ARCT score was equal or above 20 (controlled AR) and maintained for 15 days, the patient would finish the study; if ARCT score was strictly <20 (uncontrolled AR), the patient would receive higher step treatment according to a predefined open design up to Step 5. The different AR control subgroups were compared. RESULTS: A total of 255 patients were enrolled in the study; 5 patients dropped out and 2 (0.8%) were controlled at day 0, 85 (34.0%) at day 15, 177 (70.8%) at day 30, 222 (88.8%) at day 45, 241 (96.4%) at day 60 and 242 (96.8%) at day 75. Only 8 (3.2%) patients remained uncontrolled at the endpoint of the study. Patients with ARIA moderate/severe or persistent symptoms, moderate/severe impaired quality of life, asthma history, rhinorrhea and cough symptoms always needed up to Step 4 (nasal corticosteroid plus antihistamine) and prolonged treatments to achieve disease control. CONCLUSIONS: The majority of AR can be controlled with standard stepwise treatment. ARCT offers an objective criterion for the stepwise pharmacotherapy of AR.


Assuntos
Rinite Alérgica/epidemiologia , Rinite Alérgica/prevenção & controle , Adolescente , Adulto , Idoso , Antialérgicos/uso terapêutico , Criança , Pré-Escolar , Comorbidade , Feminino , Humanos , Masculino , Modelos de Riscos Proporcionais , Estudos Prospectivos , Vigilância em Saúde Pública , Qualidade de Vida , Rinite Alérgica/diagnóstico , Rinite Alérgica/terapia , Fatores de Risco , Índice de Gravidade de Doença , Resultado do Tratamento , Adulto Jovem
20.
Allergy ; 71(11): 1533-1539, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27145347

RESUMO

The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.


Assuntos
Documentação , Hipersensibilidade a Drogas/diagnóstico , Cartões Inteligentes de Saúde , Documentação/métodos , Hipersensibilidade a Drogas/etiologia , Hipersensibilidade a Drogas/prevenção & controle , Europa (Continente) , Humanos , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...